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ABSTRACT
Cancer genome sequencing has implicated the cy-
tosine deaminase activity of apolipoprotein B mRNA
editing enzyme catalytic polypeptide-like (APOBEC)
genes as an important source of mutations in di-
verse cancers, with APOBEC3B (A3B) expression es-
pecially correlated with such cancer mutations. To
better understand the processes directing A3B over-
expression in cancer, and possible therapeutic av-
enues for targeting A3B, we have investigated the
regulation of A3B gene expression. Here, we show
that A3B expression is inversely related to p53 sta-
tus in different cancer types and demonstrate that
this is due to a direct and pivotal role for p53 in re-
pressing A3B expression. This occurs through the
induction of p21 (CDKN1A) and the recruitment of
the repressive DREAM complex to the A3B gene pro-
moter, such that loss of p53 through mutation, or
human papilloma virus-mediated inhibition, prevents
recruitment of the complex, thereby causing elevated
A3B expression and cytosine deaminase activity in
cancer cells. As p53 is frequently mutated in cancer,
our findings provide a mechanism by which p53 loss
can promote cancer mutagenesis.
INTRODUCTION
The APOBEC3 family of cytosine deaminases are medi-
ators of intrinsic immunity to retroviruses and endoge-
nous retrotransposons, which act by causing cytosine-to-
uracil (C-to-U) deamination in single-stranded DNA that
is generated during reverse transcription (1,2), to pro-
mote deleterious mutations. The seven members of the
APOBEC3 gene family (A3A/B/C/D/F/G/H), are related
to the APOBEC1, APOBEC2, APOBEC4 and activation-
induced deaminase (AID). APOBEC1 functions in RNA
editing and DNA editing by AID is required for class-
switch recombination and somatic hypermutation of im-
munoglobulin genes in B cells to augment antibody diver-
sity (3). Additionally, apolipoprotein B mRNA editing en-
zyme catalytic polypeptide-like (APOBEC) genes, in par-
ticular AID, have been implicated in the epigenetic regu-
lation of gene expression by directing the deamination of
5-hydroxymethylcytosine generated by TET enzyme con-
version of 5-methylcytosine (for reviews see refs. (4–6)).
Here, deamination by AID facilitates base excision repair,
resulting in cytosine demethylation. Moreover, we recently
reported a DNA methylation-independent role for A3B-
mediated cytidine deamination and repair as a mechanism
for chromatin remodelling that facilitates estrogen receptor
(ER) target gene expression in breast cancer cells (7).
The mutational capacity of APOBECs has led to the pro-
posal that inappropriate and/or upregulated expression of
these genes could promote mutations in genomic DNA, a
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possibility bolstered by the demonstration that AID can
cause chromosomal mutations and rearrangements (8–10)
and AID, as well as APOBEC1 promote tumourigene-
sis in transgenic mouse models (11–13). Ectopic expres-
sion studies in yeast and mammalian cells have shown that
APOBEC3 enzymes can also promote mutations in ge-
nomic DNA (14–17). Importantly, sequencing of cancer
genomes reveals that a large proportion of somatic mu-
tations in diverse cancer types, including breast, ovarian,
cervical, bladder, head and neck and lung cancer, are at-
tributable to APOBEC activity (17–23). A3B is the only one
of the 11 APOBEC genes that is consistently expressed at
high levels in these cancer types and A3B expression corre-
lates with the number of C-to-T and overall mutational load
in cancer genomes (17,21,24). Genome sequencing of yeast
cells expressing A3B identify kataegic mutational patterns
similar to those that are observed in breast cancer genomes
(25) and the incidence of C-to-T mutations in breast can-
cer cells is reduced by A3B knockdown (17). Together, these
studies provide a compelling case for A3B as a driver of the
mutational landscape and tumour evolution in many com-
mon cancers.
Gene expression analysis shows that A3B levels are low in
normal tissues, but are elevated in many cancer types (7,17).
Understanding the mechanisms that regulate A3B expres-
sion will provide important insights into the processes driv-
ing acquisition of cancer mutations and tumour evolution.
Originally cloned on the basis of its induction by phorbol
ester treatment of normal keratinocytes, A3B expression is
stimulated byNF-Bactivation by protein kinase C (26,27).
Interestingly,mutational signatures associatedwithA3B ac-
tivity are especially strong in cervical and head/neck can-
cers, in which human papillomaviruses (HPV) are impor-
tant causative agents (20,21,28). Recently, the E6 and E7
viral oncogenes in high-risk HPVs were shown to promote
A3B expression (29–32), highlighting a potential explana-
tion for the A3B-associated mutator phenotype in HPV-
positive cervical and head/neck cancer. As inhibition of
p53 tumour suppressor activity/levels is a key function of
E6 (33), we reasoned that p53 might be a direct regulator
of A3B expression. Here, we show that p53 represses A3B
expression and cytosine deaminase activity in cancer cells,
through a p21-dependent mechanism and that loss of p53
activity through its mutation or HPV-16 E6/E7-mediated
downregulation, causes A3B upregulation. Further, by as-
sessing cellular cytosine deaminase activity and abasic site
generation in genomicDNA, we show that loss of p53 activ-
ity through mutation or HPV-directed downregulation can
promote increased mutagenic capacity of normal and can-
cer cells.
MATERIALS AND METHODS
Cell lines
Cell lines were obtained from ATCC (LGC Standards,
UK) and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% foetal calf serum (FCS).HCT116
p53−/− and HCT116 p21−/− cells were kindly provided
by Dr B. Vogelstein (34,35). NIKS cell lines have been
described previously (36), and were maintained at sub-
confluence on  -irradiated J2–3T3 feeder cells in com-
plete F medium, as described (37). Nutlin-3 (Bio-Techne
Ltd, UK) was added to a final concentration of 10 M,
unless otherwise stated. An equal volume of dimethyl-
sulphoxide (DMSO) was added to the vehicle controls.
HPV16 E6 and p53-interaction defective E6 mutant, Ad-
dgene ID #44152 and 44153, respectively, were a gift from
P. Howley (38). The vector, MSCV-N- GFP (Addgene ID:
37855) was a gift from K. Munger (39). Retroviral con-
structs pLXSN, pLXSN HPV16 E6, pLXSN HPV16 E7
and pLXSN HPV16 E6/E7 were kindly provided by Dr
Denise Galloway (40). For the generation of HPV-16 E6-
SAT mutant, wild-type (WT) E6 was mutated using Pfu-
Ultra DNA polymerase (Stratagene, London, UK) and the
following primer pair: E6SAT forward
5′-GCAATGTTTCAGGACCCACAGGAGAGCGC
CACAAAGTTACCACAGTTATGCACAGAGCTGC
-3′;
E6SAT reverse 5′-GCAGCTCTGTGCATAACTGTG
GTAACTTTGTGGCGCTCTCCTGTGGGTCCTGA
AACATTGC-3′.
Breast cancer samples
The patients presented with primary, operable breast can-
cer to the Dundee Cancer Centre between 1997 and 2012
and provided written, informed consent for research use of
their tissues. Use of the clinical material and data were ap-
proved by the Tayside Tissue Bank under delegated author-
ity from the Tayside Local Research Ethics Committee. To-
tal RNA was extracted from tumour samples using the Qi-
agen RNA extraction kit and cDNA was prepared using
the High Capacity cDNA Reverse Transcription Kit and
oligo-dT primers (Applied Biosystems), according to man-
ufacturer’s instructions. Polymerase chain reaction (PCR)
with p53-specific primers (5′-TTCCACGACGGTGACAC
GCT, 5′-CTTCTGACGCACACCTATTG) was used to
amplify full length p53 cDNA, followed by Sanger sequenc-
ing to identify p53 mutations. Thirty of the 32 mutant sam-
ples encoded TP53 mutations/deletions described in the
IARC TP53 database (41). Of the remaining samples, one
case had a 3-nt deletion causing loss of Ala159 in exon 5,
the second featured a single C insertion that would cause a
frameshift after Pro309 in exon 9.
Immunoblotting
Whole cell lysates were prepared in RIPA buffer supple-
mented with protease and phosphatase inhibitor cocktails
(Roche, UK), and immunoblotted as described (7). The
A3B antibody has been described previously (7). Anti-
bodies for p21 (sc-397), p53 (sc-126), survivin (BIRC5;
sc17779), cyclin B1 (CCNB1; sc-752), E2F4 (sc-866), LIN9
(sc-398234) and HPV16 E7 (sc-6981) were purchased
from Santa Cruz Biotechnology Inc. (Germany). ß-actin
(ab6276) and MDM2 (ab16895) antibodies were obtained
from (Abcam plc, UK). The Lin54 (A303–799A-M) anti-
body was from Bethyl Laboratories Inc. (USA). HPV16 E6
antibody was from Arbor Vita corporation (CA, USA).
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Real-time RT-PCR (RT-qPCR) and ChIP-qPCR assay
Total RNA was extracted from cells in culture, as described
(7). Taqman Gene Expression Assays (Applied Biosystems,
UK) were used for RT-qPCR on an ABI 7900HT machine
and are detailed in Supplementary Data. Chromatin prepa-
ration and immunoprecipitation (ChIP) was performed ex-
actly as described previously (7). Primer sequences for
qPCR and ChIP antibodies are listed in Supplementary
Data.
RNA interference
The reverse transfection method using Lipofectamine
RNAiMAX (Invitrogen, Thermofisher Scientific, UK) was
usedwith double-strandedRNAoligonucleotides (siRNA),
as described previously (7). Nutlin was added after 48 h
and RNA and protein lysates were prepared a further 24
or 48 h later, as appropriate. ON-TARGETplus human
siRNA for E2F4 (J-003471–12), Lin9 (L-018918–01), Lin54
(L-019325–01), p53 (L-003329–00) and p21 (J-003471–12)
were purchased from Dharmacon, Thermofisher Scientific,
UK.
CRISPR-Cas9 for disruption of the TP53 gene
CRISPR-mediated deletion of sequences in the third cod-
ing exon of the p53 (TP53) gene was carried out using an
Amaxa Type II nucleofector (Lonza, Cologne, Germany)
and the MCF7 transfection protocol recommended by the
manufacturer. This involved co-transfection of U6 pro-
moter based expression plasmids for CRISPR138077 (5′-A
CACCGGCGGCCCCTGCACC-3′) and CRISPR138076
(5′-GGGCAGCTACGGTTTCCGTC-3′), described pre-
viously (42) and a hCas9 expression plasmid (a gift
from George Church; Addgene plasmid #41815). Follow-
ing nucleofection, cells were allowed to grow in DMEM
supplemented with 10% FCS, and established colonies
were screened by PCR for the region encompassing the
two CRISPR target sites in TP53 coding exon 3, using
primers with the sequences 5′-GATGAAGCTCCCAGA
ATGCC-3′ and 5′-CACTGACAGGAAGCCAAAGG-3′,
where the PCR product for WT and exon 3-deleted TP53
gene is 311 and 226 bp, respectively.
Cytidine deaminase assay
Cells were lysed in 25 mM HEPES (pH 7.4), 10%
glycerol, 150 mM NaCl, 0.5% Triton X-100, 1 mM
ethylenediaminetetraacetic acid, 1 mM MgCl2 and 1 mM
ZnCl2, supplemented with protease inhibitors. Lysates
were incubated at 37◦C for 15 min following addition
of 2 g RNase A (Qiagen). About 1 pmol ssDNA
substrate 5′ DY782-ATTATTATTATTATTATTATTTC
ATTTATTTATTTATTTA-3′ (Eurofins, UK) and 0.75U
uracil-DNA glycosylase (NEB) were added to 10 g pro-
tein lysate at 37◦C for 1 h. A total of 10 l 1N NaOH
was added and samples incubated for 15 min at 37◦C. Fi-
nally, 10 l 1N HCl was added to neutralize the reaction
and samples were separated by electrophoresis through 15%
urea-polyacrylamide gel electrophoresis gels in Tris-borate-
EDTA (1x) at 150V for 2–3 h.
Apurinic/apyrimidinic (AP) site assay
Genomic DNA was prepared and apurinic/apyrimidinic
(AP) site determination was performed using the Oxiselect
DNA damage ELISA kit (AP sites) (STA-324), according
to manufacturer’s protocol (Cell Biolabs Inc. San Diego,
CA, USA), using the aldehyde reactive probe (ARP) DNA
standards to quantify the number of genomic AP sites.
Analysis of METABRIC breast cancers and TCGA datasets
The TCGA pan-cancer level-3 somatic mutation and RNA
expression data were downloaded from Synapse (https:
//www.synapse.org/#!Synapse:syn300013). Somatic muta-
tion data for breast cancer (BRCA), lung adenocarcinoma
(LUAD) and endometrial cancer (UCEC) from TCGA
(43), were segregated according to p53 mutational status
and mutational signatures 2 and 13, which have been as-
cribed to A3B (18), were determined for each tumour type.
The Mann–Whitney–Wilcoxon statistical test was used to
check the association between p53mutation status andA3B
gene expression and number of APOBECmutational signa-
tures 2 and 13. Association between p53 mutational status
and A3B expression was similarly determined for the 2000
breast cancer samples in METABRIC (44).
RESULTS
APOBEC3B expression is repressed by p53
Previous analyses of gene expression datasets have indicated
that A3B levels are elevated in breast cancers with somatic
mutations in the p53 gene (TP53), compared with tumours
withWTTP53 (17,45,46). In agreement with these findings,
we observed a highly significant relationship between A3B
expression and p53 mutational status in the METABRIC
(P = 7.0 × 10−8) and TCGA (P = 2.2 × 10−16) breast can-
cer cohorts (Figure 1A). An association between A3B ex-
pression and p53 mutation was also seen in lung and en-
dometrial cancer (Figure 1B). To further confirm this rela-
tionship byRT-qPCR,we analysed gene expression inRNA
prepared from115 primary breast cancers, collected prior to
any therapy. A3B expression was significantly greater in p53
mutant tumours (P= 0.006; Figure 1C) andwas also higher
in breast cancer cell lines with mutant, compared with WT
p53 (P = 0.04; Figure 1D).
In order to further understand the link between p53 sta-
tus and A3B expression, we looked for evidence of A3B reg-
ulation by p53. Treatment with the p53 activator Nutlin-3
(hereafter referred to as Nutlin) was found to reduce A3B
expression in breast cancer cell lines with WT p53 (Figure
2A and B). Nutlin did not affect A3B expression in breast
cancer cells with p53 mutations. Specificity of Nutlin action
on A3B was indicated by the fact that A3B repression oc-
curred over a Nutlin dose range and time course that re-
pressed other well-characterized p53-repressed genes (sur-
vivin, CHEK1,CHEK2) (47) andwhich induced expression
of p53-activated genes (MDM2, p21) (Supplementary Fig-
ures S1 and 2). Expression of A3B and other p53-repressed
genes was elevated and there was almost complete loss in
expression of p53-activated genes in MCF7 cells in which
the p53 gene was inactivated by CRISPR-Cas9 genome
Nucleic Acids Research, 2017, Vol. 45, No. 19 11059
Figure 1. APOBEC3B expression is elevated in breast cancer with mutated p53. (A) Analysis of A3B expression in METABRIC and TCGA breast cancer
samples. For METABRIC, p53 mutational status was available for 820 samples (n = 99 (mutant p53) and 721 (WT p53)). The TCGA dataset comprised
297 samples with mutant and 802 samples with wild-type (WT) p53. (B) A3B expression analysis for the TCGA gene expression datasets for lung and
endometrial cancer according to p53 mutational status. (C) RT-qPCR shows that A3B expression is higher in p53 mutant breast cancers than in p53 WT
tumours. A3B expression is shown relative to GAPDH levels. (D) RT-qPCR of 50 breast cancer cell lines shows that A3B expression is elevated in cell
lines with p53 mutations. A3B expression is shown relative to expression of GAPDH. Asterisks show cell lines (SkBr3, HCC38) that encode the A3A-A3B
variant and so do not express A3B.
editing (Figure 2C and D). We note that despite apprecia-
ble levels of p53 mRNA, there was no detectable p53 pro-
tein inMCF7 cells following CRIPSR-Cas9-mediated dele-
tion of exon 3. A3B expression was also elevated in p53-
null HCT116 colon cancer cells (HCT116-p53−/−), com-
pared with the isogenic line expressingWT p53 (Figure 2E).
Moreover,Nutlin did not inhibitA3B expression in p53-null
HCT116 cells. Finally, siRNA-mediated p53 knockdown
prevented A3B repression by Nutlin (Figure 2F and G).
These experiments demonstrate clearly that A3B expression
is regulated by p53 and indicate that loss of p53 activity due
to its mutation, results in elevated expression of A3B.
p53 regulation of APOBEC3B expression is mediated by the
E2F4/RB-containing DREAM repressive complex
p53 ChIP following Nutlin treatment of HCT116 cells
showed enrichment of p53 at the MDM2, GADD45A and
CDKN1A (p21) gene promoters, but not at the A3B pro-
moter (Supplementary Figure S3A). Analysis of available
ChIP-seq datasets for several cell lines also failed to pro-
vide evidence for p53 binding within 20 kb of the A3B gene
transcription start site, as exemplified for U2OS cells (48)
(Supplementary Figure S3B). There was also absence of p53
at promoters of other p53-repressed genes such as the sur-
vivin (BIRC5) gene. By contrast, Nutlin strongly promoted
p53 recruitment to the MDM2 and p21 gene promoters.
Previous studies have shown that p53 induces expres-
sion of target genes by direct recruitment to gene pro-
moters, whereas gene repression by p53 is indirect, fre-
quently involving p21 (47). p21-directed inhibition of
cyclin-dependent kinases prevents hyperphosphorylation
of p107/p130 retinoblastoma (RB) proteins, promot-
ing the conversion of the so-called multi-B-MYB-multi-
vulval class B transcription activation complex, to the
E2F4/p107/p130-containing DREAM (dimerization part-
ner, RB-like, E2F and MuvB) repressive complex (Figure
3A) (49). In p21-null HCT116 cells, Nutlin did not re-
press expression of A3B or other p53-repressed genes (Fig-
ure 3B). Inhibition of A3B expression was also blunted by
siRNA-mediated p21 knockdown (Figure 3C and D). Inhi-
bition of A3B expression by Nutlin was alleviated by E2F4
knockdown (Figure 3E and F), and was also rescued by
siRNA for Lin9 and Lin54, which are key components of
the DREAM complex (Supplementary Figure S4).
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Figure 2. p53 represses APOBEC3B expression in cancer cells. Nutlin (10 M) was added for 24 h in all experiments. (A) RT-qPCR of WT and mutant
p53 breast cancer cell lines, treated with Nutlin (n = 3). A3B expression is shown relative to GAPDH. Asterisks show significant (P < 0.05) differences
between vehicle and Nutlin-treated cells. (B) Immunoblotting of cell lysates following Nutlin treatment. The filled triangle shows position of Cyclin B1.
(C) RT-qPCR of MCF7 cells in which exon 3 of the TP53 gene was targeted using CRISPR-Cas9 (MCF7-p53). Expression of all examined genes was
significantly (P < 0.05) different between parental and p53 MCF7 cells. (D) Immunoblotting of protein lysates from MCF7 and MCF7-p53 cells. (E)
Protein lysates from HCT116 and p53-null HCT116 (HCT116-p53−/−) cells ± Nutlin. (F) Twenty-four hours following transfection of HCT116 cells with
siRNA for p53, Nutlin was added. RT-qPCR was performed using RNA prepared 48 h following addition of Nutlin. (G) Immunoblotting of HCT116
cells transfected with si-p53.
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Figure 3. p53 regulation of APOBEC3B expression is mediated by p21 acting through the E2F4 DREAM transcriptional complex. (A) Shown is a model
depicting the mechanism by which the DREAM complex regulates gene expression following p53 activation. (B) RT-qPCR for p21-null HCT116 cells
treated with Nutlin for 24 h. (C) RT-qPCR of HCT116 cells transfected with p21 siRNA. Nutlin was added for 24 h. Significant (P < 0.05; n = 3)
differences between vehicle and Nutlin-treated cells are highlighted by asterisks. (D) Immunoblotting of HCT116 cell lysates following p21 knockdown.
(E and F) RT-qPCR and immunoblotting of HCT116 cells transfected with siRNA for E2F4.
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ChIP, followed by real-time PCR (ChIP-qPCR), showed
that Nutlin stimulates E2F4, p130 and LIN9 recruitment
to the A3B gene promoter, with concomittant loss of
the transcriptional activators B-MYB and p300 (Figure
4A–F; summarized in the heat map in Figure 4I). The
Nutlin-stimulated transition from the activation complex
to the repressive complex was accompanied by reduction
in the histone marks, H3K9Ac and H3K4me3, both of
which are high at the transcription start sites of active
genes (Figure 4G and H; Supplementary Figure S3B).
KDM5A/JARID1A, originally identified as a protein that
binds to RB, contributes to the repression of E2F4 tar-
get genes by removing di- and tri-methyl groups from
H3K4 (50,51). ChIP forKDM5A showedNutlin stimulated
KDM5A recruitment to the A3B promoter (Figure 4D), ex-
plaining the reduction in H3K4me3. Nutlin treatment sim-
ilarly promoted E2F4, p130, LIN9 and KDM5A recruit-
ment to the A3B promoter and reduced B-MYB, p300,
H3K4me3 and K3K9Ac in HCT116 cells (Figure 4J and
Supplementary Figure S5A). The dependence on p53 for
the Nutlin stimulated gain of E2F4/p130/LIN9/KDM5A
at the A3B gene promoter was confirmed in p53-null
HCT116 cells (Figure 4J and Supplementary Figure S5B).
Furthermore, there was no reduction in B-MYB or p300
enrichment at the A3B gene promoter in HCT116-p53−/−
cells; nor was there a reduction in levels of histone H3
marks associated with active transcription. The importance
of p21 in directing the recruitment of the DREAM complex
was confirmed by the fact that its Nutlin promoted enrich-
ment at the A3B gene promoter was prevented in p21-null
HCT116 cells (Figure 4J and Supplementary Figure S5C).
p53 inhibits the mutational capacity of cancer cells by re-
pressing APOBEC3B expression
The above results show that p53 represses A3B expression
by directing the E2F4/p107/p130-containing DREAM
complex to the A3B promoter and predict that p53 con-
trols A3B expression to limit its mutagenic potential. In-
deed, cytosine deaminase activity was generally higher in
extracts from mutant p53 lines than in lysates from cells
with WT p53 (Figure 5A and Supplementary Figure S6A),
consistent with the elevated A3B expression levels in breast
cancer cells with mutant p53. Importantly, Nutlin reduced
cytidine deaminase activity in lysates from WT-p53 MCF7
and ZR-75–1 cells, but not in those from mutant p53 cells.
The p53-dependence of Nutlin-mediated reduction in cyto-
sine deaminase activity was confirmed in HCT116 and p53-
null HCT116 cells (Figure 5B and Supplementary Figure
S6B). Note that cytosine deaminase activity was strongly re-
duced by A3B siRNA (Figure 5C and Supplementary Fig-
ure S6C), consistent with the fact that A3B is the main
APOBEC expressed in breast cancer cells (7,17).
Cytosine deamination by APOBECs generates U:G mis-
matches that are excised by uracilDNAglycosylases, to gen-
erate apurinic/abasic sites that can be processed by AP en-
donuclease (52). The aldehyde group on the open ring of
AP sites can be labelled with an ‘ARP’ containing biotin,
thus allowing detection and quantification of AP sites in
the genome (53). Interestingly, Nutlin treatment led to re-
ductions in genomic AP sites in cells with WT-p53, but not
in cells with p53 mutations (Figure 5D). Nor did Nutlin af-
fect AP sites in p53-null HCT116 cells (Figure 5E). Further-
more, in ZR-75–1 cells, A3B knockdown reduced AP sites
and Nutlin did not further inhibit AP sites, indicating that
the reduction in abasic sites is almost entirely mediated by
the Nutlin/p53 regulation of A3B (Figure 5F).
Sequencing of tumour DNAs representing diverse cancer
types, has identified patterns of DNA base alterations that
are characteristic of the enzymatic activity of A3B (17–23).
Interrogation of exome sequence datasets from the TCGA
database showed that the frequency ofmutations associated
with the A3Bmutational signatures was significantly higher
for mutant p53 tumours compared with WT-p53 in breast
(P= 2.07 × 10−6), lung (P= 2.53 × 10−8) and endometrial
cancer (P= 0.048) (Figure 5G). In conclusion, p53 restricts
the mutagenic activity of A3B by repressing its expression,
and loss of p53 in cancer results in elevated A3B expression,
which may promote somatic mutagenesis in cancer.
HPV E6 and E7 gene-mediated repression of p53 and the
E2F4/p107/p130-containing DREAM complex promotes
APOBEC3B expression and activity
Given that p53 downregulation and Rb family inactiva-
tion are key functional targets of the high-risk HPV E6
and E7 genes (33), we ascertained whether the transcrip-
tional mechanism for p53-mediated repression of A3B ex-
pression identified here is subverted by these viral onco-
genes. Indeed, A3B expression was elevated in HPV16 E6
transfected HCT116 cells, but was unaffected by E6 in p53-
null HCT116 cells (Figure 6A and B). Stimulation of A3B
expressionwas prevented in cells transfectedwith anE6mu-
tant that is defective for interaction with p53 (54). More-
over, E6, but not mutant E6, abrogated repression of A3B
by Nutlin. Consistent with these effects being mediated by
inhibition of p53 action by E6, p21 expression was reduced
by WT, but not mutant E6.
To further evaluate the mechanisms of E6 and E7 regu-
lation of p53 activity and consequence for A3B expression,
we repeated the analysis in human keratinocytes, the natural
HPV target cell. For this purposewe used normal immortal-
ized human keratinocytes (NIKS), a spontaneously immor-
talized but not transformed keratinocyte cell line (55), stably
expressing E6, E7, E6 and E7 (E6/E7) (36). In agreement
with the HCT116 results, p53 expression was abrogated in
NIKS transduced with E6, but not mutant E6 (Figure 6C).
This was accompanied by an increase in A3B and a reduc-
tion in expression of the p53-induced p21 andMDM2genes
(Figure 6C andD). E6 expression also prevented theNutlin-
mediated repression of A3B, survivin and cyclin B1, as well
as induction of p21 and MDM2. In concordance with the
described role for E7 in inhibiting the activity of Rb family
members, expression of A3B and the other p53-repressed
genes was elevated in E7-expressing NIKS, but E7 did not
affect direct p53 targets (p21, MDM2). In this context, the
inhibitory effect of HPV-16 E7 on p21 might contribute to
the enhanced expression of p53-repressed genes (56,57). A
recent meta-analysis of global HPV E7-regulated gene ex-
pression profiling datasets indicates that HPV-16 E7 can
indeed activate expression of DREAM complex-repressed
genes (58), including that of A3B (31,58), confirming our
Nucleic Acids Research, 2017, Vol. 45, No. 19 11063
Figure 4. ChIP analysis of DREAM complex enrichment at the APOBEC3B gene promoter. (A–H) ZR-75–1 cells were treated with Nutlin (10 M, 24
h), followed by ChIP for transcription factors in the DREAM complex and for histone marks associated with active genes. Asterisks identify significant
(P < 0.05; n = 3) differences in transcription factor recruitment and histone marks for the Nutlin-treated cells, relative to vehicle controls. (I) ChIP-qPCR
for Nutlin-treated samples are shown, as fold enrichment relative to vehicle. (J) ChIP-qPCR for the A3B gene in HCT116 cells, in p21-null or in p53-null
HCT116 cells. The heat map shows Nutlin-promoted changes in factor recruitment to the A3B gene, relative to vehicle controls. The full ChIP-qPCR data
are shown in Supplementary Figure S5.
findings.However, E7 expression had a notablymilder effect
on A3B upregulation, compared to E6 (Figure 6C and D).
This is consistent with previous studies in NIKS, where the
HPV-16 E7-mediated inhibition of RB family members and
effects on cell growth are alleviated by presence of growth
factors in culture medium (36). Cytosine deaminase activ-
ity was elevated in NIKS expressing E6 and/or E7 (Figure
6E), as was the number of abasic sites detectable in genomic
DNA (Figure 6F), consistent with elevated A3B expression
and activity.
As observed in other cell types, p53 was not recruited
to the A3B gene in NIKS (Supplementary Figure S7A).
In agreement with its role in inhibiting p53, there was re-
duced p53 recruitment at the MDM2 and p21 promoters
in E6 expressing NIKS, but not in cells expressing E7. B-
MYB and p300 recruitment, as well as histone methylation
and acetylation associated with gene activity, were elevated
by E6 (Figure 6G). Conversely, recruitment of the repres-
sive DREAM complex (E2F4, p130), as well as KDM5A,
was reduced. Whilst B-MYB and p300 recruitments were
not increased by E7, recruitment of the repressors p130
and KDM5A was reduced at the A3B promoter, accom-
panied by increased H3K4 tri-methylation. Similar results
were obtained for the other p53-repressed genes analysed
(Supplementary Figure S7). Taken together, these results
demonstrate that stimulation of A3B expression by HPV
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Figure 5. Inhibition of APOBEC3B expression by p53 controls mutagenesis in cancer cells. (A and B) Protein lysates prepared from Nutlin-treated cells
were used in an in vitro cytidine deaminase assay. Positions of the substrate (probe) and the deamination product, are labelled. (C) Cytidine deamination
with lysates prepared from ZR-75–1 cells, following transfection with two independent A3B siRNAs. (D–F) AP or abasic sites in genomic DNA were
biotin labelled by conversion with an aldehyde reactive probe (ARP) and quantification of biotinylated DNA. Asterisks show significant (P < 0.05; n = 3)
differences in AP sites for Nutlin-treated samples, relative to vehicle controls. (G) Analysis of A3B mutational signature for WT and mutant p53 in breast,
lung and endometrial cancer from TCGA. Values on the y-axis represent the number of A3B mutational signatures 2 and 13 in each cancer. P-values were
calculated using Mann–Whitney–Wilcoxon statistical test.
Nucleic Acids Research, 2017, Vol. 45, No. 19 11065
Figure 6. HPV16 E6 and E7 viral oncogenes promote APOBEC3B expression and activity by inhibiting the action of the E2F4/p107/p130 DREAM
transcriptional repression complex. (A) HCT116 and p53-null HCT116 cells were transfected with HPV16 E6 or the E6-SATmutant that does not interact
with p53. RT-qPCRwas performed using RNAprepared 24 h following addition of Nutlin (10M). Asterisks show significant (P< 0.05; n= 3) differences
in mRNA expression. (B) Cells treated as above, were processed for immunoblotting. (C) Normal immortalized human keratinocyte line (NIKS) stably
transduced with E6, the E6-SAT mutant, E7, E6/E7, E7/mutant E6 or vector only, were treated with Nutlin (10 M) for 24 h, followed by preparation
protein lysates for immunoblotting. (D) NIKS were treated as in C, followed by preparation of total RNA and RT-qPCR. Asterisks show significant
(P < 0.05) reduction in mRNA expression for Nutlin-treated samples relative to the vehicle treated NIKS for each transduced line. Cross-hatches show
significant (P< 0.05) difference in mRNA expression relative to the vehicle treated and vector transduced NIKS. Results for three experiments are shown.
(E) The in vitro cytidine deaminase assay was used to assess A3B activity in protein lysates prepared 24 h following addition of 10 M Nutlin to the E6
and E7 transduced NIKS cells. (F) Quantification of biotin-labelled ARP conversion of abasic sites in genomic DNA from E6 and E7 transduced NIKS
cells. Asterisks show significant (P < 0.05) differences in AP sites compared to vehicle-treated vector transduced NIKS; cross-hatches denote statistically
significant reduction in AP sites by Nutlin treatment for each transduction. (G) ChIP-qPCR for vector, E6 or E7 transduced NIKS cells is shown as fold
change in transcription factor/histone mark enrichment at the A3B gene promoter, relative to vehicle controls. The actual factor enrichment relative to
input is shown in Supplementary Figure S7B.
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E6 and E7 oncogenes is mediated by inhibition of the p53
directed transcriptional repression and the stimulation of
transcriptional activation by the B-MYB/E2F4/p107/p130
DREAM complex.
DISCUSSION
APOBEC3 genes play important roles in innate immunity
and act by causing hypermutation of retroviral genomes
and are implicated in reducing retrotransposon mobiliza-
tion. Theirmutational activities bring an inherent risk to the
host genome, as shown by ectopic expression of APOBEC3
genes, which can demonstrably cause genomic mutations
(14–17). Therefore, to safeguard genomic integrity, tight
regulation of APOBEC expression is necessary in order to
suppress their mutagenic potential. Indeed, there is a strong
evidence that over-expression of A3B causes hypermuta-
tion in many cancer types. We observed that A3B expres-
sion is higher in breast cancers with mutant p53 than in
those with WT p53, in agreement with previous reports
(17,45,46). We have found that a similar relationship be-
tween A3B expression and p53 status can be extended to
lung and endometrial cancer, cancer types in which the mu-
tational landscape is marked by mutations consistent with
A3B activity (20,21,23). These findings originally suggested
that A3Bmight be involved in the mutation of the p53 gene.
Indeed, A3B over-expression in breast cancer cell lines has
been reported to promote cytosine deamination in the p53
gene (17). However, the majority of p53mutations in cancer
do not appear to conform to the TCWDNAmotif targeted
by A3B, we investigated whether A3B expression is regu-
lated by p53 (ref. (59)), although as has been pointed out,
p53 mutations detected in tumours will not simply reflect
the exonic nucleotide sequence, but the selection imparted
by the resultant amino acid change (60).
Notwithstanding, we show here that p53 controls
APOBEC3B expression. Loss of p53 by siRNA-mediated
knockdown, gene disruption or HPV E6 expression, in-
creases A3B expression, while Nutlin activation of p53 re-
presses A3B expression in multiple cell types, strong evi-
dence that p53 is a negative regulator of A3B. Several mech-
anisms directing repression of p53 target genes have been re-
ported, including direct binding of p53, or indirect recruit-
ment via interaction with other transcription factors such
as NF-Y (47,61,62). Despite the presence of potential p53
response element sequences in the A3B gene (48), analysis
of diverse p53 ChIP-seq datasets provides little evidence for
p53 recruitment to the A3B promoter. Indeed, in only one
out of eight genome-wide p53 binding datasets analysed
by Menendez et al. (48) was there evidence for p53 bind-
ing at the A3B promoter, who also reported weak Nutlin-
and doxorubicin-induced p53 recruitment to the A3B gene
(48). Moreover, we did not observe enrichment of p53 at
the A3B promoter in ZR-75–1, HCT116 or NIKS, arguing
against an important role for direct or indirect p53 recruit-
ment to theA3B promoter. Furthermore, p53 activation did
not repress A3B expression in p21-null HCT116 cells and
p21 knockdown rescued A3B repression by Nutlin, demon-
strating the importance of p21 in the repression of A3B by
p53.
TheMuvB complex, together with B-MYBdrives expres-
sion of many cell-cycle regulated genes through the S phase
andG2/M, recruitment to the cell cycle genes homology re-
gion (CHR) element being mediated by the LIN54 compo-
nent of MuvB (49,63), whereas MuvB, together with E2F4
and p107/p130, known as the DREAM complex, represses
expression of these genes. E2F4 and p107/p130 recruit-
ment to this complex is promoted by p21-mediated inhi-
bition of CDK directed p107/p130 hyperphosphorylation.
ChIP experiments have demonstrated (i) the presence of B-
MYB and the MuvB subunit LIN9 at the A3B promoter,
together with the B-MYB associating p300 histone acetyl-
transferase, (ii) a reduction in B-MYB and p300 recruit-
ment upon Nutlin treatment, accompanied by stimulation
of E2F4 and p130 recruitment, as well as the RB-associated
histone lysine demethylase KDM5A, (iii) together with a
reduction in the levels of histone marks associated with
active transcription. The role of the B-MYB/MuvB com-
plex is confirmed by a recent study which showed that B-
MYB is a transcriptional driver of A3B expression and that
B-MYB and A3B expression is correlated in many can-
cer types (64). We further show that deletion of p53 or
of p21 prevented Nutlin-mediated loss of B-MYB/p300 or
gain of E2F4/p130/KDM5A. HPV16 E6 abrogated p21
expression, resulting in reduced E2F4/p130/KDM5A re-
cruitment and promoting B-MYB and p300 binding and
stimulation of activation histone marks at the A3B pro-
moter. E7 also inhibited recruitment of p130 and KDM5A,
consistent with action of E7 in inhibiting gene repression by
RB proteins (33).
The presence of E2F4, LIN9, LIN54 and p130 at theA3B
promoter are confirmed in global ChIP–chip experiments
(49,65), and identify a region in the A3B promoter encod-
ing a potential cell-cycle-dependent element and a CHR el-
ement, 5′-GGGAGGtcacTTTAAG-3′ ∼50 bp upstream of
the A3B transcription start site. Interestingly, expression of
the TEA domain (TEAD) transcription factors and their
co-activators YAP/TAZ is stimulated by HPV16 E6 di-
rected degradation of p53 andYAP/TAZ/TEADpromotes
A3B expression (32). Taken together, these findings further
support a critical role for p53 in regulating A3B expression,
with repression of A3B expression by the p53-mediated
displacement of the MYB-MuvB transcription activation
complex by the E2F4/p107/p130 DREAM transcriptional
repression complex. We would speculate that p53 also dis-
places the YAP/TAZ/TEAD complex from the A3B pro-
moter by repressing YAP, TAZ and TEAD expression.
Nutlin treatment results in high level expression of the
direct p53 target gene, the MDM2 E3 ubiquitin ligase.
MDM2 interacts with pRb to promote its ubiquitination
and proteasomal degradation (66,67).Nutlin treatment also
stimulates MDM2-dependent accumulation of hypophos-
phorylated pRb (68). Although MDM2 also interacts with
p107 and p130, it does not promote their ubiuitination
or proteasomal degradation (67). E2F1 also interacts with
MDM2 and Nutlin regulates proteasomal degradation of
E2F1 (69,70). However, we failed to observe an effect of
Nutlin on E2F4 protein levels, arguing against a role for
Nutlin and/or MDM2 driven proteasomal degradation of
p107/p130 or E2F4 in p53-mediated repression of A3B ex-
pression.
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It is nonetheless likely that other signals impact on A3B
expression by acting to alter the expression and/or activities
of one or more of the factors in theMuvB and/or DREAM
complexes. For example, it has recently been shown that the
PI3K/AKT pathway promotes gene expression by phos-
phorylating KDM5A, to relocalize it to the cytoplasm (71),
which would provide a potential mechanism for the de-
scribed high level A3B expression/activity associated with
HER2 amplification and/or PTEN loss (72). Further, co-
expression analysis of breast and other cancer types demon-
strated was reported to show strong enrichment for mitosis
and cell-cycle-associated functional ontology groups, with
A3B expression (46), which is in keeping with the estab-
lished role of MuvB and DREAM complexes in the reg-
ulating expression of cell cycle and mitosis genes (49,63).
In response to genotoxic and non-genotoxic insult that
challenges genomic integrity, p53 mediates innate tumour
suppression by altering expression of genes to favour bi-
ological functions such as cell cycle arrest, apoptosis and
senescence. Our results indicate that p53 also protects the
genome by limiting the mutational potential of genes whose
primary cellular role is in mutagenic inactivation of foreign
and mobilizable DNA. We have shown here that failure to
suppress A3B expression following mutational or viral in-
activation of p53, results in elevated A3B expression and
activity, with attendant increase in potential genetic muta-
tions, as demonstrated by the ability of activated WT, but
not mutant, p53 to suppress abasic site generation in ge-
nomic DNA and through the demonstration that the fre-
quency ofmutations ascribed toA3B activity in diverse can-
cer types is elevated in p53 mutant tumours. Interestingly,
in its recently identified role in regulating the expression of
ER target genes in breast cancer cells (7), elevated A3B ex-
pression could promote transcriptional programs that aid
breast cancer progression, which is consistent with associ-
ation between high A3B expression and poor patient sur-
vival in ER-positive breast cancer (7,46,73) and response
to the anti-estrogen tamoxifen (74). Thus, elevated A3B ex-
pression and activity due to p53 inactivation likely have im-
portant consequences for tumour development and tumour
evolution, including response to therapies, both through its
role in transcription and because of its potential for inflict-
ing mutational damage.
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